SHELTON, Conn., Feb. 11, 2016 /PRNewswire/ -- NanoViricides,
Inc. (NYSE MKT: NNVC) (the "Company") announced today that it has
entered into an agreement with the University
of Pittsburgh for the testing of its nanoviricides® drug
candidates in standard animal models of ocular virus
infections.
The research will be performed in the Charles T. Campbell
Ophthalmic Microbiology Laboratory by Dr. Eric Romanowski, Research Director. Dr.
Romanowski has extensive experience in ocular virus infections and
anti-viral agents discovery.
These animal studies will evaluate the efficacy and potency of
the Company's nanoviricides anti-viral agents in ocular viral
infections. The goal of these studies is to help select clinical
drug development candidates for treatment of ocular herpes
keratitis in humans.
"We are very pleased to have the Campbell Laboratory join our
efforts in developing a drug against Herpes Keratitis," said
Eugene Seymour, MD, MPH, CEO of the
Company, adding, "This is a renowned lab in the field of ocular
infections with substantial experience in antiviral drugs
development. We plan to perform IND-enabling efficacy studies of
our anti-viral agents at the Campbell Labs."
The Charles T. Campbell Ophthalmic Microbiology Laboratory is
part of the University of Pittsburgh
Medical Center's Eye Center (UPMC Eye Center). The UPMC Eye
Center in the Department of Ophthalmology of the University of Pittsburgh School of Medicine has one
of the top basic and clinical research programs in the country.
UPMC Eye Center's research focuses on infectious disease, ocular
immunology, molecular genetics and molecular biology of retinal
disease, glaucoma and advanced diagnostic imaging technology
development.
About NanoViricides:
NanoViricides, Inc. (www.nanoviricides.com) is a development
stage company that is creating special purpose nanomaterials for
antiviral therapy. The Company's novel nanoviricide® class of drug
candidates are designed to specifically attack enveloped virus
particles and to dismantle them. The Company is developing drugs
against a number of viral diseases including H1N1 swine flu, H5N1
bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral
diseases of the eye including EKC and herpes keratitis, Hepatitis
C, Rabies, Dengue fever, and Ebola virus, among others.
This press release contains forward-looking statements that
reflect the Company's current expectation regarding future events.
Actual events could differ materially and substantially from those
projected herein and depend on a number of factors. Certain
statements in this release, and other written or oral statements
made by NanoViricides, Inc. are "forward-looking statements" within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. You should not
place undue reliance on forward-looking statements since they
involve known and unknown risks, uncertainties and other factors
which are, in some cases, beyond the Company's control and which
could, and likely will, materially affect actual results, levels of
activity, performance or achievements. The Company assumes no
obligation to publicly update or revise these forward-looking
statements for any reason, or to update the reasons actual results
could differ materially from those anticipated in these
forward-looking statements, even if new information becomes
available in the future. Important factors that could cause actual
results to differ materially from the company's expectations
include, but are not limited to, those factors that are disclosed
under the heading "Risk Factors" and elsewhere in documents filed
by the company from time to time with the United States Securities
and Exchange Commission and other regulatory authorities.
Although it is not possible to predict or identify all such
factors, they may include the following: demonstration and proof of
principle in pre-clinical trials that a nanoviricide is safe and
effective; successful development of our product candidates; our
ability to seek and obtain regulatory approvals, including with
respect to the indications we are seeking; the successful
commercialization of our product candidates; and market acceptance
of our products.
Logo - http://photos.prnewswire.com/prnh/20150107/167444LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/nanoviricides-signs-agreement-for-ocular-testing-of-its-drug-candidates-for-the-treatment-of-herpes-keratitis-with-the-university-of-pittsburgh-300218675.html
SOURCE NanoViricides, Inc.